NEXVET BIOPHARMA PLC (NVET) financial statements (2020 and earlier)

Company profile

Business Address UNIT 5, SRAGH TECHNOLOGY PARK
TULLAMORE , CO. OFFALY, R35 FR98
State of Incorp.
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3152
Cash and cash equivalents3152
Receivables03
Prepaid expense0 
Other current assets0 
Other undisclosed current assets21
Total current assets:3556
Noncurrent Assets
Property, plant and equipment51
Intangible assets, net (including goodwill)00
Intangible assets, net (excluding goodwill)00
Prepaid expense00
Deferred costs00
Other undisclosed noncurrent assets0(1)
Total noncurrent assets:50
Other undisclosed assets 1
TOTAL ASSETS:4057
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities42
Accounts payable21
Accrued liabilities00
Employee-related liabilities21
Deferred revenue and credits00
Other undisclosed current liabilities11
Total current liabilities:53
Noncurrent Liabilities
Liabilities, other than long-term debt00
Deferred revenue and credits00
Accounts payable and accrued liabilities0 
Other undisclosed noncurrent liabilities0 
Total noncurrent liabilities:00
Total liabilities:53
Stockholders' equity
Stockholders' equity attributable to parent, including:3554
Common stock11
Additional paid in capital8280
Accumulated other comprehensive loss(5)(4)
Accumulated deficit(43)(24)
Other undisclosed stockholders' equity attributable to parent00
Total stockholders' equity:3554
TOTAL LIABILITIES AND EQUITY:4057

Income statement (P&L) ($ in millions)

6/30/2016
6/30/2015
Revenues
(Revenue, Net)
 0
Cost of revenue
(Cost of Goods and Services Sold)
(0)(1)
Gross profit:(0)(0)
Operating expenses(22)(20)
Other undisclosed operating income01
Operating loss:(22)(20)
Nonoperating income04
Investment income, nonoperating00
Foreign currency transaction gain, before tax04
Net loss:(22)(16)
Other undisclosed net income attributable to parent24
Net loss available to common stockholders, diluted:(19)(12)

Comprehensive Income ($ in millions)

6/30/2016
6/30/2015
Net loss:(22)(16)
Comprehensive loss:(22)(16)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2(1)
Comprehensive loss, net of tax, attributable to parent:(20)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: